Marksans Pharma Limited has informed the Exchange that Board of Directors at its meeting held on May 19, 2025, recommended Final Dividend of 0.80 per equity share.
MARKSANS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Marksans Pharma's board approved audited consolidated and standalone financial results for Q4 and FY ended March 31, 2025, with MSKA & Associates issuing an unmodified opinion. Consolidated revenue from operations rose to Rs. 26,228 million (from Rs. 21,774 million, up about 20.5%), while consolidated profit after tax grew to Rs. 3,826 million (from Rs. 3,149 million). Standalone revenue surged to Rs. 11,744 million and PAT to Rs. 1,883 million. The board recommended a final dividend of Rs. 0.80 per share (face value Re. 1), translating to 80% for FY25, subject to shareholder approval at the upcoming AGM. Additionally, Srinivas Mishra was appointed as a Non-executive Independent Director for 5 years, and amendments to the ESOP Scheme 2024 (covering a pool of 23 lakh options) were approved.
Strong topline growth and a healthy 80% dividend payout signal robust cash generation and shareholder rewards, likely to be viewed positively by investors. The new independent director strengthens governance and the ESOP amendments align with talent retention, though any dilution from future grants should be monitored.